Official ESCRS | European Society of Cataract & Refractive Surgeons
London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here


Come to London

video-icon

WATCH to find out why


Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Accelerated cross-linking with 10mW/cm2 light in patients with keratoconus

Poster Details

First Author: P.Michieletto ITALY

Co Author(s):    A. Balestrazzi   R. Di Cicco   M. Pizzi   C. Tamburrelli     

Abstract Details



Purpose:

To evaluate the efficacy and the safety of accelerated Cross-Linking with 10mW/cm2 in patients with keratoconus

Setting:

Ophthalmic Hospital of Rome

Methods:

40 eyes of 40 patients have been treated by two surgeons with higher intensity cross linking (10mW/cm2) from october 2013 in our Department . All patients were submitted to digital slit lamp biomicroscopy, visual acuity test ,Corneal Topography, Anterior segment OCT .

Results:

In most of case demarcation line OCT was between 190 and 220 microns, we had only one postoperative complication( a large corneal infiltrate) perhaps linked to 'use of contact lenses.The postoperative course was similar to that of traditional cross linking (3mW/cm2). In rare cases we noticed slight transient corneal opacity. In all cases patients reported less discomfort and less burning during surgery with respect to traditional cross linking.

Conclusions:

Our preliminary clinical results suggest that accelerated Cross-Linking with 10mW/cm2 and standard Corneal Cross-Linking with 3mW/cm2 UV light have similar effects on the cornea, but accelerated Cross-Linking with 10mW/cm2 seems to be less invasive. Reduce the treatment time to 9 minutes can be of benefit to both the patient and surgeon and may widen the indications of this type of treatment . FINANCIAL INTEREST: NONE

Back to Poster listing